spacer
home > ebr > winter 2001 > smallpox - preventing the unthinkable
PUBLICATIONS
European Biopharmaceutical Review

Smallpox - Preventing the Unthinkable

Since the appalling events of September 11th and the subsequent anthrax scares across the United States, bioterrorism has become a very real threat to the Western world. The recent anthrax attacks have made governments around the world acknowledge the need to be able to deal quickly with bioterrorist attacks, in whatever shape or form they may come. It is also making them take notice of an even greater threat than anthrax, which if unleashed could cause misery and death worldwide - smallpox. This article explains how serious a threat this deadly virus is, and what needs to be done to prevent a potential catastrophe.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Paul Chaplin, Chief Scientific Officer and Vice President of
Research and Development at Bavarian Nordic

Paul Chaplin is the Chief Scientific Officer and Vice President of Research and Development at Bavarian Nordic. Before joining the company in 1999 as Manager of Immunology, he worked for many years in the areas of cytokine and dendritic cell biology at the Institute for Animal Health in the UK. This was followed by three years spent in the research and development of veterinary vaccines at CSIRO (Cooperative Research Centre for Vaccine Technology) in Australia. Paul was awarded his PhD in Immunology from Bristol University in the UK in 1994.

spacer
Paul Chaplin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

FlyPharma Conference Europe 2022 Shares the Latest Supply Chain Challenges and Advice for Better Industry Collaboration

On 20-21 September 2022, the FlyPharma Conference Europe made a welcome return as a live, in-person event. The conference was warmly received by its delegates and declared a resounding success, with some familiar faces from previous events and many new ones in attendance across the two days.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement